ClinicalTrials.Veeva

Find clinical trials for Non-Hodgkin Lymphoma in Valencia, VC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoid Leukemia
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Valencia, VC, ESP:

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Mosunetuzumab
Drug: Obinutuzumab

Phase 1

ADC Therapeutics

Valencia, Spain and 26 other locations

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Valencia, Spain and 73 other locations

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma (OLYMPIA-4)

is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding ...

Enrolling
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Drug: Dexamethasone
Drug: Ifosfamide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Valencia, Spain and 29 other locations

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: CC-99282
Drug: Rituximab

Phase 2

Genmab
Genmab

Hospitalet de Llobregat, Barcelona, Spain and 74 other locations

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

additional open-label imaging feasibility sub-study using a tracer in adult participants with relpased/refractory B-cell non-Hodgkin...

Active, not recruiting
Non-Hodgkins Lymphoma
Drug: Tocilizumab
Drug: Atezolizumab

Phase 1, Phase 2

Roche
Roche

Valencia, Spain and 19 other locations

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab or glofitamab in combination with CELMoDs (CC-220 or CC-99282) i...

Enrolling
Non-Hodgkin Lymphoma
Drug: IV Glofitamab
Drug: CC-99282

Phase 1

Roche
Roche

València, Valencia, Spain and 26 other locations

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

The purpose of this single-arm, open-label, Phase 1b/2a, multicenter basket study is to evaluate whether tafasitamab and parsaclisib can be safely co...

Active, not recruiting
Non Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Drug: tafasitamab
Drug: parsaclisib

Phase 1, Phase 2

Incyte
Incyte

Valencia, Spain and 49 other locations

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated (ELM-2)

according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) and as assessed by independent central review in eac-...

Enrolling
B-cell Non-Hodgkin Lymphoma (NHL)
Drug: Odronextamab

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Valencia, Spain and 137 other locations

Phase 1 First in Human Study of ZN-d5 as a Single Agent

Phase 1 dose escalation study of ZN-d5 in subjects with relapsed or refractory non-Hodgkin lymphoma (NHL) or acute myeloid...

Enrolling
Non Hodgkin Lymphoma
Acute Myeloid Leukemia
Drug: ZN-d5

Phase 1

K-Group Alpha

Valencia, Spain and 13 other locations

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma (RR-NHL), and determine the recomm...

Active, not recruiting
Neoplasm Malignant
Drug: SAR442257

Phase 1

Sanofi
Sanofi

Valencia, Spain and 15 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems